CD4 and neoplasm: Inhibiting CD39, an ecto-enzyme converting extracellular ATP to AMP, through antibody activates NLRP3 inflammasomes leading to IL-18 secreting that expands intra-tumor effector CD4+ and CD8+ T cells [210].